A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma

Conditions

Soft Tissue

Phase II

What is the purpose of this trial?

This phase II trial studies how well atezolizumab works in treating patients with alveolar soft part sarcoma that has not been treated, has spread from where it started to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as atezolizumab, may allow the immune system cells to find and kill the tumor cells.

  • Trial with
    National Cancer Institute
  • Start Date
    05/21/2018
  • End Date
    11/30/2018

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Matthew Piscatelli

  • Last Updated
    11/27/2018
  • Study HIC
    #2000021392